Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

NIAID Awards Funding for Non-Needle Anthrax Vaccine

by Global Biodefense Staff
October 20, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Pfenex, Inc., a contract to develop an alternative dry formulation delivery method for the company’s recombinant Protective Antigen (rPA)-based anthrax vaccine. 

The base award of $2.18 million may be expanded to a total of $22.9 million over the course of the contract if all options are exercised.

Under an existing BARDA contract, Pfenex has successfully developed a novel rPA that is highly immunogenic and protective in animal studies, with a scalable production process and robust yields, anticipated to allow dose and antigen sparing.

Development of a needle-free dry formulation under the new funding is anticipated to create a vaccine stable for long term storage and facilitate ease of administration, overcoming two important logistical constraints of the currently available vaccines.

“Pfenex is pleased to be awarded this contract from NIAID to progress an additional development path for our anthrax vaccine program,” stated Bertrand C. Liang, Pfenex Chief Executive Officer. “We believe this important countermeasure effort can provide a solution to the US government quest to stockpile sufficient vaccine doses to rapidly respond to an anthrax biothreat.”

The NIAID contract (HHSN272201200033C) was managed under Broad Agency Announcement entitled “Vaccine Technologies to Advance Next Generation Anthrax Vaccines” (BAA-NIAID-DMID-NIHAI201010).

Source: Pfenex.com

 

Tags: AnthraxASPRAwardsBARDABioterrorismHHSStrategic National StockpileVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC